Here’s what you should know:
1. The system is the first and only FDA-approved system that simultaneously provides paresthesia-based and sub-perception therapy.
2. The Spectra WaveWriter system allows physicians and patients to combine therapeutic options with sub-perception therapies. The system captures real-time feedback to allow for a better pain treatment experience.
3. The system works by using low electrical pulses, which vary in frequency, width and amplitude and are delivered to the spinal cord, interrupting pain signals.
4. Boston Scientific spent more than a decade developing the SpectraWave system. The system has been tested and shown to be effective through several studies.
Boston Scientific’s President and Senior Vice President of Neuromodulation Maulik Nanavaty said, “We are introducing industry-leading SCS technology to help provide patients with lasting relief from chronic pain. We are committed to investing in research and expanding treatment options for chronic pain by identifying new, non-opioid solutions for the millions of people suffering from this debilitating condition.”
More articles on spine:
MUSC to open outpatient surgical facility in mall: 5 key points
Dr. Bhupinder Khaira, North Texas Medical Center partner to operate outpatient surgery location: 4 key points
Parkview Medical Center opens new outpatient center — 6 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.